By the same authors

From the same journal

From the same journal

Analytic considerations in applying a general economic evaluation reference case to gene therapy

Research output: Contribution to journalArticle

Standard

Analytic considerations in applying a general economic evaluation reference case to gene therapy. / Drummond, M.F.; Neumann, P.; Sullivan, S.; Fricke, F.U.; Tunis, S.; Dabbous, O.; Toumi, M.

In: Value in Health, Vol. 22, No. 6, 12.06.2019, p. 661-668.

Research output: Contribution to journalArticle

Harvard

Drummond, MF, Neumann, P, Sullivan, S, Fricke, FU, Tunis, S, Dabbous, O & Toumi, M 2019, 'Analytic considerations in applying a general economic evaluation reference case to gene therapy', Value in Health, vol. 22, no. 6, pp. 661-668. https://doi.org/10.1016/j.jval.2019.03.012

APA

Drummond, M. F., Neumann, P., Sullivan, S., Fricke, F. U., Tunis, S., Dabbous, O., & Toumi, M. (2019). Analytic considerations in applying a general economic evaluation reference case to gene therapy. Value in Health, 22(6), 661-668. https://doi.org/10.1016/j.jval.2019.03.012

Vancouver

Drummond MF, Neumann P, Sullivan S, Fricke FU, Tunis S, Dabbous O et al. Analytic considerations in applying a general economic evaluation reference case to gene therapy. Value in Health. 2019 Jun 12;22(6):661-668. https://doi.org/10.1016/j.jval.2019.03.012

Author

Drummond, M.F. ; Neumann, P. ; Sullivan, S. ; Fricke, F.U. ; Tunis, S. ; Dabbous, O. ; Toumi, M. / Analytic considerations in applying a general economic evaluation reference case to gene therapy. In: Value in Health. 2019 ; Vol. 22, No. 6. pp. 661-668.

Bibtex - Download

@article{65b4392a4dc841d0b9ef8a9ba220b8cd,
title = "Analytic considerations in applying a general economic evaluation reference case to gene therapy",
abstract = "The concept of a reference case, first proposed by the US Panel on Cost-Effectiveness in Health and Medicine, has been used to specify the required methodological features of economic evaluations of health care interventions. In the case of gene therapy, there is a difference of opinion on whether a specific methodologic reference case is required. The aim of this paper is to provide a more detailed analysis of the characteristics of gene therapy and the extent to which these characteristics warrant modifications to the methods suggested in general reference cases for economic evaluation. We argue that a completely new reference case is not required, but propose a tailored checklist that can be used by analysts and decision-makers to determine which aspects of economic evaluation should be considered further, given the unique nature of gene therapy.",
keywords = "cost-effectiveness analysis;, drug pricing;, reimbursement, specialty drugs",
author = "M.F. Drummond and P. Neumann and S. Sullivan and F.U. Fricke and S. Tunis and O. Dabbous and M. Toumi",
note = "{\circledC} 2019, ISPOR–The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc. This is an author-produced version of the published paper. Uploaded in accordance with the publisher’s self-archiving policy.",
year = "2019",
month = "6",
day = "12",
doi = "10.1016/j.jval.2019.03.012",
language = "English",
volume = "22",
pages = "661--668",
journal = "Value in Health",
issn = "1098-3015",
publisher = "Elsevier Inc.",
number = "6",

}

RIS (suitable for import to EndNote) - Download

TY - JOUR

T1 - Analytic considerations in applying a general economic evaluation reference case to gene therapy

AU - Drummond, M.F.

AU - Neumann, P.

AU - Sullivan, S.

AU - Fricke, F.U.

AU - Tunis, S.

AU - Dabbous, O.

AU - Toumi, M.

N1 - © 2019, ISPOR–The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc. This is an author-produced version of the published paper. Uploaded in accordance with the publisher’s self-archiving policy.

PY - 2019/6/12

Y1 - 2019/6/12

N2 - The concept of a reference case, first proposed by the US Panel on Cost-Effectiveness in Health and Medicine, has been used to specify the required methodological features of economic evaluations of health care interventions. In the case of gene therapy, there is a difference of opinion on whether a specific methodologic reference case is required. The aim of this paper is to provide a more detailed analysis of the characteristics of gene therapy and the extent to which these characteristics warrant modifications to the methods suggested in general reference cases for economic evaluation. We argue that a completely new reference case is not required, but propose a tailored checklist that can be used by analysts and decision-makers to determine which aspects of economic evaluation should be considered further, given the unique nature of gene therapy.

AB - The concept of a reference case, first proposed by the US Panel on Cost-Effectiveness in Health and Medicine, has been used to specify the required methodological features of economic evaluations of health care interventions. In the case of gene therapy, there is a difference of opinion on whether a specific methodologic reference case is required. The aim of this paper is to provide a more detailed analysis of the characteristics of gene therapy and the extent to which these characteristics warrant modifications to the methods suggested in general reference cases for economic evaluation. We argue that a completely new reference case is not required, but propose a tailored checklist that can be used by analysts and decision-makers to determine which aspects of economic evaluation should be considered further, given the unique nature of gene therapy.

KW - cost-effectiveness analysis;

KW - drug pricing;

KW - reimbursement

KW - specialty drugs

U2 - 10.1016/j.jval.2019.03.012

DO - 10.1016/j.jval.2019.03.012

M3 - Article

VL - 22

SP - 661

EP - 668

JO - Value in Health

T2 - Value in Health

JF - Value in Health

SN - 1098-3015

IS - 6

ER -